S&P 500 (SPY)
Stocks will look to continue where they left off last week, and likely continue to work there way towards 3,150 on the S&P 500. The market continues to feel like it wants to go up, pretty much holding steady on negative headlines, and pushing higher on positive headlines.
Russel 2000 (IWM)
Meanwhile, we will continue to wait for the Russell 2000 to break out. The index has been unable to get above 1,600 for some time.
AMD seems to be on a course that will end up sending the stock back to prices not seen since 2006, at roughly $42.
Microsoft is likely to continue to push higher this week with the potential to make it to around $152 in the not to distance future.
Intel is testing a break out of its own around $59 with the potential for a push higher to prices not seen since September 2000 at $64.
Beyond Meat (BYND)
Beyond Meat has acted very well at support around $78. I thought it would fill the gap $100 last week; it stands a better chance this week.
Micron failed at resistance at $48.75 this past week, and it doesn’t bode well for my call for the stock to rise to $53 I noted on November 5 – Micron Is Breaking Out
Acadia finally made it to resistance at $48.10; now, it needs to break out to get back to it all-time $52. The way the stock traded last week on strong volume, one has to think there is news coming soon.
Biogen keeps slipping lower, and now it is at support at $280. The big question is if it fills that gap down at $225. Ouch. It may. Maybe not this week, but if breaks support, watch out.
Source: Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future results.